ARGS - Argos Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Argos Therapeutics, Inc.

4233 Technology Drive
Durham, NC 27704
United States
919-287-6300
http://www.argostherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees39

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey D. AbbeyPres, CEO & Director832.98kN/A1962
Dr. Richard D. KatzVP & CFON/AN/A1964
Dr. Charles A. NicoletteChief Scientific Officer and VP of R&D465.54kN/A1962
Mr. William N. WoffordSec.N/AN/AN/A
Ms. Lori R. Harrelson CPA, CPAVP of Fin.N/AN/A1969
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Corporate Governance

Argos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.